Connection of miR-185 and miR-320a expression levels with response to interferon-beta in multiple sclerosis patients.

Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by neurodegeneration in the CNS. Interferon-beta (IFN-β) is an FDA-approved drug used as the first-line treatment for relapse-remitting multiple sclerosis (RRMS). The exact mechanism of IFN-β during the treatment of RRMS still remains unknown. Recently, many studies have shifted towards the role of miRNAs in the treatment of MS patients. Herein, the expression level of miR-185-5p and miR-320a has been evaluated in order to candidate them as novel biomarkers for monitoring the response to IFN-β therapy. For this purpose, one-hundred whole blood samples from patients with RRMS were collected, consisting of 50 responders and 50 non-responders to IFN-β therapy. To predict the possible molecular mechanisms of IFN-β and highlight the role of these miRNAs, in silico analysis was applied to enrich the signaling pathways which may be involved based on the target genes of miR-185-5p and miR-320a. It is identified that the differentially expressed miR-185-5p was statistically significant between the two treated groups with IFN-β. Furthermore, MAPK signaling pathway was suggested as the main non-canonical pathway involved in IFN-β therapy. miR-185-5p could be considered as a novel biomarker for monitoring the response to IFN-β therapy. Copyright © 2020 Elsevier B.V. All rights reserved.

Citation

Seyyed Reza Mousavi, Mahsa Tahmasebivand, Mehdi Khorrami, Hormoz Ayromlou, Soodabeh Khalil Khalili, Fariborz Khorvash, Reza Rikhtegar, Bahareh Khademi, Zahra Bahmanpour, Babak Emamalizadeh. Connection of miR-185 and miR-320a expression levels with response to interferon-beta in multiple sclerosis patients. Multiple sclerosis and related disorders. 2020 Sep;44:102264

Mesh Tags

Substances

PMID: 32554287

search → result